Delivery Order SPE2DB22D9207-SPE2DB25FH5DM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a direct procurement for pharmaceutical products supporting Department of Defense healthcare needs. The contract...
- The Defense Logistics Agency awarded a $12.78K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240 count). The contract, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a firm fixed-price delivery order with no set-aside designation. This award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-unit quantity) with a ceiling value of $25,564.66. This firm fixed-price delivery order, awarded on August 18, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). This firm fixed-price delivery order, awarded on July 21, 2025, carries a ceiling value of $12,782.32 and is scheduled for ultimate completion by August 11, 2025. The contract was awarded without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $49,897.20 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Alecensa 150 mg capsules. This order is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC allows the DLA to issue delivery orders for a wide range of pharmaceutical products to support the medical...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,782.32 contract is for the delivery of 240 capsules of the drug Alecensa (150 mg) to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,782.32 contract is for the supply of Alecensa 150 mg capsules to support the medical needs of the Department of Defense. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order from the Defense Logistics Agency for 240 units of Alecensa 150 mg capsules, valued at $21,731.14. This firm fixed-price delivery order, awarded on August 4, 2025, with an ultimate completion date of August 25, 2025, carries no set-aside designation. The award represents one of numerous delivery orders issued under DMS Pharmaceutical Group's larger...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $49,897.20 contract is for the delivery of Alecensa 150 mg capsules. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical...
- This is a $12,782.32 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Alecensa 150 mg capsules and has an ultimate completion date of June 18, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through...
- SPE2DB22D9207Indefinite Delivery Contract
- SPE2DB22D9207-SPE2DB25FH5DMDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,782.32 to DMS Pharmaceutical Group Inc. for the supply of Alecensa 150 mg capsules (240-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge location with an ultimate completion date of September 10, 2025. This award carries no set-aside designation, allowing the vendor to compete on an unrestricted basis despite its small business status. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the Defense Logistics Agency, valued at $499.999 billion and valid through November 2026. The parent IDC, administered under the SPE2DB program, authorizes DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting medical supply needs across Department of Defense healthcare facilities worldwide. Alecensa, an oncology medication, aligns with the parent contract's coverage of prescription drugs and specialty medications essential to military health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.8k | 8/19/25 |